| Literature DB >> 31227884 |
L Johansson1,2, H K Svensson3,4,5, J Karlsson5, L-E Olsson3,4,5, D Mellström1,6, M Lorentzon1,6, D Sundh7,8.
Abstract
In a population-based study of older Swedish women, we investigated if clinical vertebral fracture was associated with lower health-related quality of life (HRQoL) and determined whether the association remained over time. Clinical vertebral fracture was associated with lower HRQoL and the effect persisted for up to 18.9 years.Entities:
Keywords: HRQoL; Older women; VFA; Vertebral fractures
Mesh:
Year: 2019 PMID: 31227884 PMCID: PMC6795611 DOI: 10.1007/s00198-019-05044-0
Source DB: PubMed Journal: Osteoporos Int ISSN: 0937-941X Impact factor: 4.507
Baseline characteristics for morphometric and time-dependent clinical vertebral fracture and women without fracture
| No fracture ( | VFA-Frx ( | Clinical vertebral Frx-T1 ( | Clinical vertebral Frx-T2 ( | Clinical vertebral Frx-T3 ( | |||
|---|---|---|---|---|---|---|---|
| Time since spine fracture, years | – | 1.84 (1.21–3.05) | 7.86 (5.18–9.98) | 18.9 (15.8–23.9) | |||
| Age, years | 77.7 ± 1.65 | 78.0 ± 1.55 | 78.2 ± 1.39 | 78.2 ± 1.60 | 78.3 ± 1.66 | ||
| Height, cm | 162.0 ± 5.74p | 161.2 ± 5.74& | 160.9 ± 6.63# | 159.8 ± 5.25‰a | 162.5 ± 7.03∞∑a | ||
| Weight, kg | 68.8 ± 12.1 | 68.5 ± 11.3 | 0.65 | 68.9 ± 12.9 | 66.8 ± 13.5 | 68.8 ± 11.9 | 0.78 |
| Lumbar spine aBMD, g/cm2 | 0.96 ± 0.18 | 0.93 ± 0.16 | 0.92 ± 0.16 | 0.93 ± 0.17 | 0.95 ± 0.16 | 0.19 | |
| PCS | 46.2 ± 10.6Ω | 44.7 ± 11.0O | 36.3 ± 10.8∆c | 41.0 ± 9.94#‰b€a | 41.6 ± 11.4æb∂a | ||
| MCS | 53.4 ± 9.20Ω | 53.3 ± 10.1O | 0.88 | 52.3 ± 10.1 | 56.0 ± 8.19# | 51.5 ± 11.2 | 0.12 |
| PASE | 105 ± 50.5† | 101 ± 48.6O | 0.11 | 83.8 ± 47.0∆b | 108 ± 43.3€a | 90.6 ± 47.9 | 0.01 |
| One-leg standing, s | 14.4 ± 9.70ø | 12.3 ± 8.97r | 12.1 ± 10.5£ | 13.0 ± 8.59$ | 14.4 ± 10.3§ | 0.54 | |
| Grip strength, kg | 15.0 ± 5.46¶ | 14.2 ± 5.17s | 13.5 ± 6.31 | 13.8 ± 5.57# | 13.8 ± 6.07 | 0.08 | |
| Chair stands, number/30s | 11.5 ± 3.49¥ | 11.0 ± 3.50t | 10.7 ± 3.08¢ | 11.1 ± 3.20‡ | 10.0 ± 3.25◊ æa | ||
| Current osteoporosis medication, | 73 (4.9) | 33 (9.1) | 22 (51.2) | 17 (39.5) | 14 (31.8) | ||
| Current smoking, | 90 (6.1) | 19 (5.2) | 0.54 | 2 (4.7) | 2 (4.7) | 3 (6.8) | 0.95 |
| Chronic bronchitis, asthma, or emphysema, | 134 (9.0) | 38 (10.5) | 0.40 | 7 (16.3) | 5 (11.6) | 5 (11.4) | 0.38 |
| Excessive alcohol consumption, | 10 (0.7) | 3 (0.8) | 0.76 | 1 (2.3) | 0 (0.0) | 0 (0.0) | 0.51 |
| Rheumatoid arthritis, | 55 (3.7) | 17 (4.7) | 0.39 | 0 (0.0) | 2 (4.7) | 1 (2.3) | 0.57 |
| Glucocorticoid use, | 43 (2.9) | 17 (4.7) | 0.09 | 1 (2.3) | 2 (4.7) | 2 (4.5) | 0.83 |
| Heredity of hip fracture, | 238 (16.1) | 64 (17.6) | 0.47 | 10 (23.3) | 9 (20.9) | 8 (18.2) | 0.51 |
| Prior stroke, | 90 (6.1) | 27 (7.4) | 0.34 | 4 (9.3) | 7 (16.3) | 1 (2.3) |
Data is presented for non-fractured controls and participants with a morphometric vertebral fracture (VFA-Frx) and clinical vertebral fractures divided by tertiles dependent on time since spine fracture. If normally distributed, continuous variables are presented as mean ± standard deviation otherwise as median and interquartile range. Differences were compared with an independent sample t test for the VFA-Frx and for the tertiles, an ANOVA followed by a least significant difference post hoc test was used. Dichotomous variables are presented as percentage (number of subjects) and differences in proportions were compared with a chi-squared test. Significant p values are presented in italic numbers. aBMD, areal bone mineral density; PCS, physical component score; MCS, mental component score; PASE, physical activity scale for the elderly; T1, tertile 1; T2, tertile 2; and T3, tertile 3
Differences between different tertiles and controls: ∆clinical vertebral Frx-T1 vs. controls, ‰clinical vertebral Frx-T2 vs. controls, æclinical vertebral Frx-T3 vs. controls, €clinical vertebral Frx-T2 vs. clinical vertebral Frx-T1, ∂clinical vertebral Frx-T3 vs. clinical vertebral Frx-T1, ∑clinical vertebral Frx-T3 vs. clinical vertebral Frx-T2
ap < 0.05, bp < 0.01 cp < 0.001
Each column presents the maximum number of participants and deviations are denoted for each variable by the following: 1481, Ω1480, †1477, ¶1424, ¥1406, ø1228, o362, &361, s349, t338, r286, ∞43, #42, ◊38, ‡37, $33, ¢31, §29, £28
Baseline characteristics for time-dependent hip fractures and women without fracture
| No fracture ( | Hip Frx-T1 ( | Hip Frx-T2 ( | Hip Frx-T3 ( | ||
|---|---|---|---|---|---|
| Time since spine fracture, years | – | 2.11 (1.08–2.49) | 5.10 (4.42–6.39) | 14.6 (10.8–19.8) | |
| Age, years | 77.7 ± 1.65 | 78.1 ± 1.65 | 78.6 ± 1.60‰a | 78.2 ± 1.45 | |
| Height, cm | 162.0 ± 5.74p | 163.5 ± 6.62 | 160.8 ± 7.74 | 163.2 ± 6.35 | 0.42 |
| Weight, kg | 68.8 ± 12.1 | 69.3 ± 11.5 | 60.9 ± 13.1‰b€a | 66.2 ± 13.6 | |
| Lumbar spine aBMD, g/cm2 | 0.96 ± 0.18 | 0.87 ± 0.15 | 0.91 ± 0.11 | 0.95 ± 0.13 | 0.05 |
| PCS | 46.2 ± 10.6Ω | 40.7 ± 11.8∆a | 42.7 ± 11.6 | 42.4 ± 10.6 | |
| MCS | 53.4 ± 9.20Ω | 54.4 ± 8.09 | 54.0 ± 9.43 | 51.0 ± 10.7 | 0.67 |
| PASE | 105 ± 50.5† | 92.7 ± 43.5 | 108 ± 74.9 | 78.0 ± 49.2 | 0.10 |
| One-leg standing, s | 14.4 ± 9.70ø | 11.6 ± 10.2£ | 13.3 ± 10.3$ | 9.80 ± 8.60§ | 0.28 |
| Grip strength, kg | 15.0 ± 5.46¶ | 15.8 ± 4.22∞ | 13.8 ± 8.23# | 13.7 ± 4.92# | 0.54 |
| Chair stands, number/30s | 11.5 ± 3.49¥ | 10.3 ± 4.62‡ | 10.3 ± 2.64◊ | 9.77 ± 3.52£ | 0.11 |
| Current osteoporosis medication, | 73 (4.9) | 8 (40.0) | 6 (33.3) | 5 (27.8) | |
| Current smoking, | 90 (6.1) | 0 (0.0) | 4 (22.2) | 1 (5.6) | |
| Chronic bronchitis, asthma, or emphysema, | 134 (9.0) | 2 (10.0) | 1 (5.6) | 5 (27.8) | 0.05 |
| Excessive alcohol consumption, | 10 (0.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0.94 |
| Rheumatoid arthritis, | 55 (3.7) | 1 (5.0) | 2 (11.1) | 1 (5.6) | 0.41 |
| Glucocorticoid use, | 43 (2.9) | 1 (5.0) | 2 (11.1) | 0 (0.0) | 0.17 |
| Heredity of hip fracture, | 238 (16.1) | 5 (25.0) | 3 (16.7) | 5 (27.8) | 0.41 |
| Prior stroke, | 90 (6.1) | 4 (20.0) | 1 (5.6) | 2 (11.1) | 0.07 |
Data is presented for women with a reported hip fracture divided by tertiles dependent on time since hip fracture and women with no fracture. If normally distributed, continuous variables are presented as mean ± standard deviation otherwise as median and interquartile range. Differences were compared with ANOVA followed by a least significant difference post hoc test. Dichotomous variables are presented as percentage (number of subjects) and differences in proportions were compared with a chi squared test. Significant p values are presented in italic numbers. aBMD, areal bone mineral density; PCS, physical component score; MCS, mental component score; PASE, physical activity scale for the elderly; T1, tertile 1; T2, tertile 2; and T3, tertile 3
Differences between different tertiles and controls: ∆Hip Frx-T1 vs. controls, ‰Hip Frx-T2 vs. controls, €Hip Frx-T2 vs. Hip Frx-T1
ap < 0.05, bp < 0.01
Each column presents the maximum number of participants and deviations are denoted for each variable by the following: p1481, Ω1480, †1477, ¶1424, ¥1406, ø1228, ∞19, #17, ‡16, ◊15, £13, §12, $9
Fig. 1Physical component score (PCS), obtained from the SF12 questionnaire. Comparison between controls (without any fracture) and women with a clinical vertebral fracture according to tertiles of time since fracture. Differences were compared with ANOVA and following post hoc analyses were performed with least significant difference (LSD) and significant levels are presented as **p < 0.01, ***p < 0.001
Fig. 2Physical component score (PCS), obtained from the SF12 questionnaire: comparison between controls (without any fracture) and women with a hip fracture according to tertiles of time since fracture. Differences were compared with ANOVA and following post hoc analyses were performed with least significant difference (LSD) and significant levels are presented as *p < 0.05
Baseline characteristics for number and severity of morphometric vertebral fractures and women without fracture
| No fracture ( | One ( | Two ( | More than two ( | Mild ( | Moderate ( | Severe ( | |||
|---|---|---|---|---|---|---|---|---|---|
| Age, years | 77.7 ± 1.65 | 78.0 ± 1.55 | 78.0 ± 1.59 | 78.0 ± 1.57 | 77.9 ± 1.53 | 78.1 ± 1.59‰b | 77.7 ± 1.53 | ||
| Height, cm | 162.0 ± 5.74p | 161.4 ± 5.69# | 161.3 ± 5.62∞ | 158.2 ± 5.96æb∂b∑a | 161.9 ± 5.66 | 161.0 ± 5.77ö‰a | 159.1 ± 5.48mæb∂b∑a | ||
| Weight, kg | 68.8 ± 12.1 | 68.5 ± 11.0 | 70.2 ± 11.8 | 62.9 ± 12.6 | 0.08 | 69.1 ± 10.8 | 68.1 ± 11.1 | 67.3 ± 13.5 | 0.72 |
| Lumbar spine aBMD, g/cm2 | 0.96 ± 0.18 | 0.94 ± 0.16 | 0.90 ± 0.17 | 0.85 ± 0.15 | 0.95 ± 0.16 | 0.92 ± 0.17 | 0.89 ± 0.15 | ||
| PCS | 46.2 ± 10.6Ω | 44.7 ± 10.8#∆a | 46.5 ± 10.8 | 40.0 ± 12.8æb∂a∑a | 44.7 ± 10.7 | 45.9 ± 10.7ö | 41.0 ± 12.3æc∂a∑b | ||
| MCS | 53.4 ± 9.20Ω | 53.2 ± 9.80# | 53.3 ± 11.0 | 54.1 ± 10.6 | 0.97 | 53.9 ± 8.90 | 53.1 ± 10.6ö | 52.1 ± 12.0 | 0.65 |
| PASE | 105 ± 50.5† | 102 ± 46.5# | 102 ± 57.2 | 84.7 ± 46.4 | 0.17 | 99.7 ± 43.4 | 106 ± 53.1ö | 86.1 ± 48.3æb∑a | |
| One-leg standing, s | 14.4 ± 9.70ø | 12.7 ± 9.05$∆a | 10.5 ± 7.77§‰b | 12.1 ± 11.4£ | 12.6 ± 9.21k∆a | 12.9 ± 8.75h | 8.72 ± 8.11gæb∂a∑a | ||
| Grip strength, kg | 15.0 ± 5.46¶ | 14.5 ± 5.24◊ | 13.8 ± 5.01∞ | 12.4 ± 4.63æa | 14.8 ± 5.24v | 14.5 ± 4.98o | 11.5 ± 4.78qæc∂c∑c | ||
| Chair stands, number/30s | 11.5 ± 3.49¥ | 10.9 ± 3.32‡ | 11.4 ± 4.46ä | 10.8 ± 2.28å | 0.09 | 11.0 ± 3.20w | 11.2 ± 3.88x | 10.2 ± 3.18dæa | |
| Current smoking, | 90 (6.1) | 12 (4.4) | 3 (4.5) | 4 (16.7) | 0.09 | 6 (3.7) | 10 (6.6) | 3 (6.0) | 0.65 |
| Chronic bronchitis, asthma, or emphysema, | 134 (9.0) | 27 (9.9) | 8 (12.1) | 3 (12.5) | 0.77 | 13 (8.0) | 19 (12.6) | 6 (12.0) | 0.43 |
| Excessive alcohol consumption, | 10 (0.7) | 3 (1.1) | 0 (0.0) | 0 (0.0) | 0.74 | 2 (1.2) | 0 (0.0) | 1 (2.0) | 0.40 |
| Rheumatoid arthritis, | 55 (3.7) | 14 (5.1) | 2 (3.0) | 1 (4.2) | 0.71 | 8 (4.9) | 5 (3.3) | 4 (8.0) | 0.39 |
| Glucocorticoid use, | 43 (2.9) | 9 (3.3) | 5 (7.6) | 3 (12.5) | 4 (2.5) | 8 (5.3) | 5 (10.0) | ||
| Heredity of hip fracture, | 238 (16.1) | 45 (16.5) | 15 (22.7) | 4 (16.7) | 0.56 | 31 (19.1) | 28 (18.5) | 5 (10.0) | 0.39 |
| Prior stroke, | 90 (6.1) | 17 (6.2) | 5 (7.6) | 5 (20.8) | 12 (7.4) | 9 (6.0) | 6 (12.0) | 0.36 |
Vertebral fracture assessment was used to establish the number and severity of morphometric vertebral fractures. Results are presented as mean ± standard deviation for the continuous variables and percentages together with number of participants for the dichotomous variables. Differences for number and severity of morphometric vertebral fracture were investigated with an ANOVA followed by a least significant difference post hoc test. PCS, physical component score; MCS, mental component score; PASE, physical activity scale for the elderly. A p value below 0.05 was considered significant. Differences between number and severity of morphometric vertebral fractures and controls: ∆one/mild vs. controls, ‰ = two/moderate vs. controls, æmore than two/severe vs. controls, ∂more than two/severe vs. one/mild, ∑more than two/severe vs. two/moderate
ap < 0.05, bp < 0.01 cp < 0.001
Each column presents the maximum number of participants and deviations are denoted for each variable by the following: Ω1480, †1477, ¶1424, ¥1406, ø1228, #272, ‡261, ◊260, $221, w155, v154, ö150, o149, x139, k138, h118, ∞65, ä59, §51, m49, q46, d44, g30, å18, £14
Physical function (PCS) over time after a clinical vertebral fracture
| Unstandardized β | ||
|---|---|---|
| All clinical vertebral fractures | − 6.04 | < 0.001 |
| Clinical vertebral fracture in tertile 1 (1.84 [1.21–3.05] years) | − 9.21 | < 0.001 |
| Clinical vertebral fracture in tertile 2 (7.86 [5.18–9.98] years) | − 4.97 | 0.001 |
| Clinical vertebral fracture in tertile 3 (18.9 [15.8–23.9] years) | − 4.02 | 0.01 |
Linear regressions were adjusted for age, height, weight, current smoking, MCS, prior stroke, grip strength, and lumbar spine BMD. Results are presented as beta coefficients per increase. Clinical vertebral fracture divided by tertiles according to time (presented as median and interquartile range) since most recent clinical vertebral fracture, p value below 0.05 was considered statistically significant